Mobilise-D and Cure Parkinson’s UK in strategic partnership to accelerate the translation of research into clinical practice

We are excited to announce our strategic partnership with Cure Parkinson’s UK, working closely together to bring our research and clinical studies closer to patients and the public. We asked Helen Matthews, Deputy CEO of Cure Parkinson’s, to share with us her vision about the benefits of the research and clinical trials in Parkinson’s Disease,…

Episode 3: Making a difference in people’s lives – Silvia Del Din awarded a NUAcT Fellowship.

Our Mobilise-D colleague Dr. Silvia Del-Din has always been fascinated by research and the idea of “making a difference in people’s lives”. Here she explains her role in Mobilise-D, her new NUAcT fellowship at Newcastle University, and her perspective on how remote monitoring can revolutionize healthcare.  Silvia (37) was born in Agordo in the North-East of Italy and is a great fan of travelling and hiking. In her professional life, she has been involved in research for more than 10 years now. But how did a young girl from a small town nestled in the Dolomites, end up doing…

In the spotlight: Abolfazl Soltani’s Public PhD defense, Friday, Dec 11

This coming Friday Abolfazl Soltani, one of our Mobilisers from EPFL, Switzerland, will have the public defense of his PhD thesis.  In his PhD work, Abolfazl has focused on accurate walking speed estimation and walking bout detection based on wrist-worn sensors. Although there are many different digital systems that can monitor gait in unsupervised free-living situations such as housekeeping, catching a bus, and shopping, they each have different advantages and disadvantages.   One such system, the Global Navigation Satellite System (GNSS), can measure real-world gait speed accurately, but…

New publication: A roadmap to inform development, validation and approval of digital mobility outcomes: the Mobilise-D approach

Well known biomarkers such as blood pressure, respiration, temperature, pulse, and pain are frequently used by physicians and other health professionals to describe a patient’s health and disease status. In addition to these ‘signs of life’, there is another important aspect of people’s health and disease status, namely their mobility – how well they walk. Loss of physical mobility, such as reduced walking speed, is a significant feature of many health…

EMA Public Support for Mobilise-D

In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of…

NIHR NEWS: Monitoring patients’ mobility continues despite new lockdown

Monitoring patients’ mobility during the COVID19 pandemic could easily have been impossible due to lockdown and restrictions such as social distancing. However, this isn’t the case for the Mobilise-D technical validation study (TVS) where 120 participants with chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, congestive heart failure or hip fracture, along with healthy older adults, will be enrolled. Our test sites in Newcastle and Sheffield have found a way to work around the distancing restrictions to keep the study open, and confirmed that the technical validation…